The $16,000 Longevity Stack: When Optimization Starts Missing the Obvious

A $16,000 annual supplement routine is bound to attract attention, but the money is almost beside the point.

The routine includes fish oil, krill oil, C15:0, urolithin A, nicotinamide riboside, spermidine, curcumin, creatine, antioxidants, magnesium, glycine, inositol and several other compounds intended to influence glucose regulation, cognition, inflammation and mitochondrial function. It eventually moves beyond supplements into peptides and an investigational metabolic drug.

Several of those choices are reasonable. Some have useful human data behind them. Others are supported mainly by early clinical research, observational findings or plausible biological mechanisms. A few remain firmly experimental.

Once everything is assembled into a single “longevity stack,” those differences can become surprisingly hard to see.

We sell supplements

That is worth saying at the beginning.

HormoneSynergy® uses supplements in clinical care. We formulate them. We sell them. We believe well-selected nutritional products can correct deficiencies, support specific clinical goals and complement a larger treatment plan.

Because we participate in the supplement business, we think we have an obligation to be particularly clear about where supplements fit.

Our own practical longevity supplement discussion includes omega-3s, vitamin D, magnesium, creatine and other nutrients that may be useful depending on diet, laboratory findings, medications and individual needs.

Creatine is a good example. It has been studied for decades. Its role in cellular energy metabolism is well understood, evidence supporting strength and resistance-training adaptation is substantial, and research into healthy aging and cognition continues to grow.

That body of evidence is not equivalent to evidence for every compound associated with an interesting aging pathway.

Good supplementation begins with knowing the difference.

Medicine, Not Marketing also applies to longevity medicine

Modern longevity medicine has remarkable tools. We can measure coronary plaque, visceral fat, muscle mass, bone density, insulin resistance, lipoproteins, inflammation and cognitive performance. We can prescribe medications that did not exist a generation ago. The biology of aging is being studied at a level that would have seemed impossible only a few decades ago.

None of it has made basic physiology obsolete.

The American Heart Association's Life's Essential 8 remains almost stubbornly ordinary: diet, physical activity, tobacco exposure, sleep, body weight, cholesterol, blood glucose and blood pressure.

These factors are not fashionable longevity biomarkers. They are major determinants of cardiovascular and metabolic health.

Many of them cost little or nothing to improve.

A walk after dinner does not require a subscription. Neither does going to bed earlier. Not smoking saves money. Resistance training can be done with basic equipment. Drinking less alcohol often reduces spending. Managing blood pressure is inexpensive compared with treating a stroke.

Supplements may add something useful to that foundation. They cannot become the foundation.

Where the biology gets ahead of the evidence

Longevity research is full of compelling mechanisms. NAD+ is involved in cellular energy and repair. AMPK and mTOR participate in nutrient sensing. Autophagy helps cells recycle damaged components. Mitochondria are central to energy production and cellular signaling.

Researchers should be studying all of these pathways.

The difficult part is translating a biological effect into something that matters clinically.

A compound may raise NAD+, alter inflammatory signaling or improve a mitochondrial biomarker without showing that the person taking it will experience fewer cardiovascular events, less dementia, better physical function or longer survival.

Urolithin A has progressed farther than many longevity compounds. Randomized human trials have reported effects on muscle endurance and mitochondrial measures, which makes the research genuinely interesting. A 2026 review of randomized trials still found a relatively small, short-term and heterogeneous evidence base. There is enough there to keep watching. There is not enough to describe it as established longevity therapy.

C15:0, or pentadecanoic acid, has also attracted substantial attention. Observational studies and laboratory research have suggested potentially favorable biological effects, and it has even been proposed as an essential fatty acid. A 2026 analysis found that some favorable observational associations were not supported by Mendelian-randomization evidence of a causal cardiovascular benefit.

This is how emerging science normally works. Early findings create good questions. Larger and better studies eventually tell us which ideas survive.

The diet deserves the same scrutiny as the supplements

The author describes himself as eating roughly 80–90% meat, avoiding most vegetables and greens, and viewing carnivore eating favorably, particularly as an elimination strategy.

There are situations in which a temporary elimination diet can be useful. Simplifying food intake may help identify triggers when someone has significant gastrointestinal or other food-related symptoms.

That is different from establishing near-exclusive meat consumption as a long-term strategy for cardiovascular health, cognitive health or longevity.

The human evidence for long-term carnivore eating remains remarkably limited. A 2026 scoping review found only nine human studies published between 2021 and 2025. Most were small, short and frequently lacked control groups. Some reported weight loss, greater satiety or improvements in selected metabolic measures. Concerns included very low fiber intake, possible micronutrient inadequacies and increases in LDL cholesterol.

A small 2025 exploratory study shows why sweeping claims in either direction are difficult. Participants reported some health improvements, and selected metabolic markers improved in some individuals. Median LDL cholesterol rose from 157 mg/dL before the diet to 256 mg/dL while participants were following it.

HormoneSynergy® is not anti-meat. Animal protein can be an excellent source of protein and micronutrients, and maintaining adequate protein intake becomes increasingly important with age. Meat, fish, eggs and dairy can all fit comfortably within a healthy diet.

Our general approach is protein-forward and plant-forward, with many of the features associated with Mediterranean-style eating.

There is also an obvious question raised by combining a highly restrictive diet with a very large supplement routine. If entire categories of food disappear from the diet and additional products are then needed to fill nutritional or fiber gaps, at least part of the stack may be compensating for choices made elsewhere.

That possibility deserves as much attention as the supplement labels.

Vitamin D and the word “optimal”

The routine includes 12,000 IU of vitamin D3 each day and identifies a blood level of 60–80 ng/mL as an important goal.

HormoneSynergy® uses vitamin D, monitors vitamin D and individualizes treatment. We do not believe clinical decisions should be reduced to whether a laboratory result sits inside a printed reference range.

We are equally cautious about replacing the reference interval with a universal high target and calling it optimal.

The Endocrine Society's 2024 vitamin D guideline concluded that clinical trials have not established outcome-specific blood concentrations for disease prevention. In generally healthy adults younger than 75 without another indication for treatment, the guideline suggested against routinely taking vitamin D above established dietary reference intakes solely for disease prevention.

Someone with deficiency, malabsorption, bone disease, medication effects, minimal sun exposure or another clinical reason may need a different approach.

The dose should follow the person and the clinical purpose. The person should not be made to chase the number.

Omega-6, omega-3 and the search for a perfect ratio

The same routine places considerable emphasis on avoiding seed oils and maintaining an omega-6:omega-3 ratio near 3:1.

Omega-3 status can be useful information. EPA and DHA have important physiological roles, and there are situations in which omega-3 testing helps clarify intake or treatment.

The ratio is harder to interpret than it appears. Two people can have the same omega-6:omega-3 ratio while having very different absolute concentrations of both groups of fatty acids. Human cardiovascular research also does not support treating omega-6 fats broadly as inflammatory nutrients that should simply be driven downward.

We are generally more interested in whether EPA and DHA intake is adequate, what the entire dietary pattern looks like and what clinical problem is being addressed.

A ratio can provide information. It does not need to become another score to optimize.

Retatrutide belongs in another category

Retatrutide is not a supplement. It is an investigational medication being developed by Eli Lilly that acts at the GIP, GLP-1 and glucagon receptors.

The clinical results are impressive. Phase 3 findings reported in 2026 showed substantial weight loss and meaningful metabolic improvement, and retatrutide could eventually become an important addition to obesity medicine.

As of September 2026, it remains investigational and has not been FDA-approved. Lilly has stated that products claiming to be retatrutide outside Lilly-sponsored clinical trials are not Lilly-manufactured retatrutide. The FDA currently states that retatrutide cannot legally be used in human drug compounding under federal law.

Clinical trial results for Lilly's drug do not tell us the identity, purity, concentration or manufacturing quality of an unrelated product sold under the same name.

HormoneSynergy® follows metabolic medicine closely and uses FDA-approved GLP-1 medications when appropriate. Pharmaceutical sourcing is part of medical care, not an administrative detail.

Six and a half hours of sleep

This may be the most interesting detail in the entire routine.

The author reports sleeping about 6.5 hours a night while identifying executive function, mood, brain health and inflammation as major priorities.

Individual sleep needs vary, and duration is not the only measure that matters. Sleep quality, consistency, apnea and circadian timing all deserve consideration. For most adults, however, 6.5 hours is not an obvious example of an optimized sleep foundation.

Sleep affects glucose regulation, appetite, blood pressure, immune function, mood, cognition and exercise recovery. We discuss many of these relationships in our article on sleep and metabolic health.

Someone may spend hundreds of dollars trying to influence inflammation, cognition and mitochondrial function while leaving one of the most powerful regulators of those same systems partially addressed.

An additional hour of sleep is considerably less interesting than a novel molecule. It also does not come with a monthly invoice.

Exercise still has one of the best returns in medicine

Regular aerobic activity and resistance training influence insulin sensitivity, blood pressure, cardiovascular fitness, muscle mass, bone health, mood, cognition and physical independence.

The recommendations remain familiar: regular aerobic activity combined with muscle-strengthening exercise throughout the week.

The importance of strength becomes more obvious with age. Healthspan includes carrying groceries, climbing stairs, getting off the floor, recovering from illness and remaining independent.

Creatine can help support training. Protein can help support recovery. Neither produces the adaptations that come from actually using muscle, bone, heart and lungs.

The cardiovascular work still comes first

A sophisticated supplement routine does not protect someone from untreated cardiovascular risk.

Blood pressure matters. ApoB and other atherogenic lipoproteins matter. Diabetes and insulin resistance matter. Visceral fat matters. Smoking matters. Fitness matters. Family history and genetics matter. Existing plaque matters.

When those risks are present, lifestyle changes and appropriate medications are backed by evidence that extends far beyond a laboratory mechanism.

This is why HormoneSynergy® spends so much time on preventive cardiology, vascular assessment and body composition. Finding coronary plaque, vascular disease, visceral fat, muscle loss or metabolic dysfunction can change what we do for a patient.

The purpose of advanced testing is not to accumulate an impressive collection of biomarkers. It is to identify something important enough to change care.

Biomarkers are useful, but they do not answer every question

The author deserves credit for measuring his physiology rather than simply assuming that the products are working. He reports actual omega-3 and vitamin D results and appears to take testing seriously.

That is preferable to guessing.

A biomarker can still change without improving healthspan. A supplement can move a laboratory value without reducing cardiovascular events, dementia, disability or mortality. It is also possible to optimize one number while overlooking something more important elsewhere.

HormoneSynergy® uses advanced diagnostics because good measurements can expose risk and guide treatment. We also ask whether a test will change anything meaningful before attaching too much importance to the result.

Most of the foundation is not for sale

This may explain why the fundamentals receive less attention than they deserve.

There is little recurring revenue in telling someone to take a walk after dinner. Nobody can patent a consistent bedtime. Avoiding cigarettes requires no proprietary formula. Maintaining relationships, moving outdoors, eating largely unprocessed food and training your muscles do not fit easily into a monthly subscription.

Medicine nevertheless has decades of evidence behind those behaviors.

Supplements remain useful when there is a reason to use them. A good product may correct a deficiency, support a defined clinical need or add something worthwhile to an otherwise strong plan. Some people will also choose to experiment with emerging compounds before definitive outcome data exist, provided they understand the uncertainty.

What supplements cannot do is allow us to buy our way around basic physiology.

Medicine, Not Marketing

The $16,000 price tag makes this routine memorable, but cost is not how we judge an intervention.

An inexpensive product with little evidence can still be a poor investment. An expensive medication or diagnostic test that meaningfully changes disease risk may be worth every dollar.

We care about the reason something is being used. We want to know what evidence supports it, how it compares with other ways of addressing the same problem, what risks come with it and whether we can tell if it is accomplishing anything useful. We also want to know whether it still deserves a place six months or a year later.

That is what Medicine, Not Marketing means to us.

HormoneSynergy® will continue to use supplements. We will continue to formulate them. We will continue to follow research into mitochondrial health, NAD+, urolithin A, creatine, omega-3s, peptides, GLP-1 medications and whatever comes next.

We will also keep asking where those interventions belong.

For most people, there is still enormous room to improve healthspan through sleep, physical activity, muscle, nutritious food, tobacco avoidance, sensible alcohol use, blood pressure control and careful management of cardiovascular and metabolic risk.

Supplements can be part of that work. They should never make us forget the work itself.

Frequently Asked Questions

Does HormoneSynergy® oppose longevity supplements?

No. HormoneSynergy® uses, formulates and sells supplements. We believe they can be useful when they address a nutritional need, support a specific clinical objective or complement a larger treatment plan. We also believe their evidence, limitations and role should be discussed openly.

Is a carnivore diet proven to extend healthspan?

No. Long-term human evidence for carnivore diets remains very limited. A 2026 scoping review found only nine human studies and described possible short-term benefits alongside concerns involving fiber intake, micronutrient adequacy and LDL cholesterol. A temporary elimination diet used for a specific purpose is not the same as an established long-term longevity diet.

Is taking a large number of supplements necessarily dangerous?

No. The number of products alone does not determine safety. Risk depends on ingredients, doses, medical history, medications, interactions, product quality and duration of use. Large regimens can make it harder to determine what is helping, what is unnecessary and what may be causing unwanted effects.

Is retatrutide FDA-approved?

No. As of September 2026, retatrutide remains investigational and has not been FDA-approved. The FDA currently states that retatrutide cannot legally be used in human drug compounding under federal law.

Should everyone try to reach a vitamin D level of 60–80 ng/mL?

No. Randomized clinical trials have not established a universal disease-prevention target of 60–80 ng/mL. Vitamin D dosing and blood-level goals should be considered in the context of diet, sun exposure, absorption, bone health, medications, medical history and laboratory findings.

Selected Evidence

• American Heart Association. Life's Essential 8. Cardiovascular-health framework addressing diet, physical activity, tobacco exposure, sleep, weight, cholesterol, blood glucose and blood pressure.
• Lietz A, Dapprich J, Fischer T. Carnivore Diet: A Scoping Review of the Current Evidence, Potential Benefits and Risks. Nutrients. 2026.
• Klement RJ, et al. Subjective Experiences and Blood Parameter Changes in Individuals From Germany Following a Self-Conceived “Carnivore Diet”: An Explorative Study. 2025.
• Endocrine Society. Vitamin D for the Prevention of Disease: An Endocrine Society Clinical Practice Guideline. 2024.
• American Academy of Sleep Medicine and Sleep Research Society. Recommended Amount of Sleep for a Healthy Adult: A Joint Consensus Statement.
• Liu S, et al. Effect of Urolithin A Supplementation on Muscle Endurance and Mitochondrial Health in Older Adults: A Randomized Clinical Trial. JAMA Network Open.
• 2026 systematic review and meta-analysis of randomized human trials examining urolithin A and muscle-health outcomes.
• Steffen LM, et al. 2026 analysis of plasma pentadecanoic acid, cardiovascular health and Mendelian randomization.
• U.S. Food and Drug Administration. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. Current 2026 guidance regarding retatrutide.
• Eli Lilly and Company. What to Know About Retatrutide. 2026.

This article is for educational purposes and is not individualized medical advice. Supplements, medications and investigational compounds should be evaluated in the context of personal medical history, laboratory findings, current medications, diet, lifestyle and clinical goals.